Pfs230 is essential for Plasmodium falciparum transmission to mosquitoes and is the protein
targeted by the most advanced malaria-transmission-blocking vaccine candidate. Prior …

Malaria transmission-blocking vaccines (TBVs) aim to induce antibodies that interrupt
malaria parasite development in the mosquito, thereby blocking onward transmission, and …

Transmission-blocking vaccines have the potential to be key contributors to malaria
elimination. Such vaccines elicit antibodies that inhibit parasites during their development in …

Pfs230 is a leading malaria transmission blocking vaccine (TBV) candidate. Comprising
3135 amino acids (aa), the large size of Pfs230 necessitates the use of sub-fragments as …

The Plasmodium falciparum Pf s230 and Pf s48/45 proteins are expressed during
transmission from man to mosquito and are leading candidates for a malaria transmission …

Summary Pfs230 domain 1 (Pfs230D1) is an advanced malaria transmission-blocking
vaccine antigen demonstrating high functional activity in clinical trials. However, the …

Abstract The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading malaria transmission-
blocking vaccine antigen. Pfs25 vaccination is intended to elicit antibodies that inhibit …

Among the Plasmodium falciparum surface antigens reported by Richard Carter and his
colleagues decades ago, Pfs230 is currently the target of the most advanced candidate for a …

ABSTRACT Production of Pfs25, a Plasmodium falciparum transmission-blocking vaccine
target antigen, in functional conformation with the potential to elicit effective immunogenicity …

Transmission-blocking vaccines are based on eliciting antibody responses in the vertebrate
host that disrupt parasite development in the mosquito vector and prevent malaria …